BBIO
Live chart
What they do
BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM).
For information only · Important disclosures
Grades vs sector
No sector grades for BBIO yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.
Our models
Not held by any of our 5 live models right now.
News
More newsKey stats
Valuation and fundamentals
Valuation & fundamentals
Discounted cash flow
Edit assumptions · recalculates instantly
Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 0.97 × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.
Multiples vs sector
Forward EPS $-0.22 vs trailing $-3.56. Forward P/E uses analysts' next-12-month estimate.
Quality & financial health
Altman Z-score -3.2 (distress zone; above 3.0 = safe, below 1.8 = distress). Not meaningful for banks and insurers.
Analysts
Annual history
| FY | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $502.1M | – | $-447.0M |
| 2024 | $221.9M | – | $-521.7M |
| 2023 | $9.3M | – | $-529.0M |
| 2022 | $77.6M | – | $-424.3M |
| 2021 | $69.7M | – | $-511.2M |
| 2020 | $8.2M | – | $-407.2M |
From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR +86.3%.
Earnings
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-08-10 | -0.58 | -0.78 | -33.9% |
| 2026-05-07 | -0.62 | -0.84 | -36.2% |
| 2026-02-24 | -0.62 | -0.94 | -50.6% |
| 2025-10-29 | -0.78 | -0.72 | +7.7% |
| 2025-08-05 | -0.60 | -0.95 | -57.1% |
| 2025-04-29 | -1.00 | -0.99 | +0.9% |
| 2025-02-20 | -1.09 | -1.37 | -26.1% |
| 2024-11-12 | -0.86 | -1.08 | -25.1% |
Quarterly revenue
| Quarter | Revenue | YoY |
|---|---|---|
| 2026-06-30 | $243.7M | +120.4% |
| 2026-03-31 | $194.5M | – |
| 2025-12-31 | $154.2M | – |
| 2025-09-30 | $120.7M | – |
| 2025-06-30 | $110.6M | – |
Analyst actions
PT $87
PT $91
PT $120
PT $156
PT $120
PT $120
Insider trades
$89.0K
$601.9K
$8.6K
$152.4K
$679.3K
$100.4K
$1.2M
$1.4M
$154.2K
$160.1K
–
–
Stats refreshed 2026-10-21 17:57:55 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
Independent research · Not investment advice · Important disclosures · Contact desk@coteau.app
Coteau Systematic Strategies publishes stock research and model portfolios. Results are hypothetical unless marked Live. Data: Yahoo Finance (15-min delayed), SEC EDGAR and the House Clerk.
Beta 0.9 · Oct 21, 2026